Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort - Summary - MDSpire

Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort

  • By

  • Roberta Elisa Rossi

  • Matteo Ferraris

  • Lorenzo Petronio

  • Benedetta Masoni

  • Luca Di Stefano

  • Alexia Francesca Bertuzzi

  • Sara Fraticelli

  • Andrea Gerardo Antonio Lania

  • Alessandro Zerbi

  • Cesare Hassan

  • Alessandro Repici

  • July 7, 2026

  • 0 min

Share

Objective:

To evaluate the occurrence of T1gNETs in AIG patients and identify associated clinical, biochemical, and histological factors.

Approach:
  • Study Design: Retrospective analysis of histologically confirmed AIG patients at Humanitas Research Hospital from January 2020 to February 2025.
  • Data Collection: Clinical, biochemical, and histological variables were extracted from a dedicated database.
  • Statistical Analysis: Associations between T1gNETs incidence and risk factors were tested using chi-square, Spearman, and Mann-Whitney tests.
Key Findings:
  • 16% of AIG patients were diagnosed with T1gNETs (p-value not provided).
  • ECL cell hyperplasia was the strongest histological factor associated with T1gNETs (OR = 3.65, p = 0.0109).
  • Dyspeptic symptoms showed a significant inverse correlation with tumor occurrence (OR = 0.35, p = 0.035).
  • No significant predictive value was found for smoking, alcohol, BMI, or severe hypergastrinemia/CgA levels.
Interpretation:

AIG patients have a significantly elevated occurrence of T1gNETs, with ECL hyperplasia being a key associated factor.

Limitations:
  • Single-center study may limit generalizability.
  • Retrospective design may introduce selection bias.
Conclusion:

Further data are needed to better understand the implications of these findings.

Original Source(s)

Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort

  • by Roberta Elisa Rossi, Matteo Ferraris, Lorenzo Petronio, Benedetta Masoni, Luca Di Stefano, Alexia Francesca Bertuzzi, Sara Fraticelli, Andrea Gerardo Antonio Lania, Alessandro Zerbi, Cesare Hassan, Alessandro Repici

  • July 7, 2026

Related Content

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial

AI Framework Helps Identify New CAR T Target

A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models

  • July 6, 2026

  • 3 min
Clinical response to FGFR inhibitors in patients with FGFR2-amplified advanced gastric cancer: two case reports